Characteristics and baseline laboratory data of 17 patients with relapsed acute promyelocytic leukemia treated with oral As2O3
Patient no. . | Sex/age, y . | LVEF, % . | Previous treatment . | Creatinine level, μM . | Na level, mM . | K level, mM . | Ca level, mM . | Status* . | Outcome† . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F/40 | 55 | ATRA, Dauno | 81 | 141 | 3.7 | 2.41 | CR | CR, 22 mo+ |
| 2 | F/49 | 78 | ATRA, Dauno, VP-16, Ara-C, IDA | 85 | 142 | 3.5 | 2.47 | CR | CR, 85 mo+ |
| 3 | F/35 | 75 | ATRA, Dauno, VP-16, IDA, Ara-C | 59 | 139 | 4.2 | 2.39 | CR | CR, 49 mo+ |
| 4 | F/32 | 65 | ATRA, Dauno, VP-16 | 82 | 141 | 3.8 | 2.46 | CR | CR, 26 mo+ |
| 5 | M/41 | 55 | ATRA, Dauno, Ara-C | 89 | 139 | 2.8 | 2.39 | CR | CR, 55 mo+ |
| 6 | M/76 | 50 | ATRA, Dauno | 146 | 135 | 4.1 | 2.48 | Dead | Sepsis, 15 d |
| 7 | M/46 | 65 | Dauno, VP-16 | 87 | 144 | 3.5 | 2.25 | CR | CR, 26 mo+ |
| 8 | F/55 | 50 | IDA | 87 | 143 | 3.4 | 2.43 | CR | CR, 21 mo+ |
| 9 | M/48 | 50 | ATRA, Dauno, Ara-C, VP-16 | 100 | 140 | 3.6 | 2.38 | CR | CR, 40 mo+ |
| 10 | M/64 | 50 | ATRA, Dauno, Ara-C, IDA | 143 | 141 | 4.3 | 2.27 | CR | CR, 49 mo+ |
| 11 | F/50 | 50 | Dauno, Ara-C, VP-16 | 100 | 137 | 3.9 | 2.30 | CR | CR, 65 mo+ |
| 12 | M/37 | 50 | ATRA, Dauno, Ara-C, VP-16 | 78 | 140 | 3.8 | 2.40 | CR | Dead, R3, 16 mo |
| 13 | M/40 | 65 | ATRA, Dauno, VP-16, Ara-C, IDA | 126 | 135 | 3.7 | 2.33 | CR | CR, 15 mo+ |
| 14 | M/44 | 55 | ATRA, Dauno, Ara-C, VP-16 | 73 | 141 | 3.6 | 2.36 | CR | Dead, TB, 12 mo |
| 15 | M/44 | 50 | ATRA, Dauno, VP-16 | 68 | 142 | 3.6 | 2.38 | CR | CR, 31 mo+ |
| 16 | M/28 | 75 | ATRA, Dauno, VP-16 | 73 | 141 | 3.8 | 2.38 | CR | CR, 11 mo+ |
| 17 | M/31 | 65 | ATRA, Dauno, Ara-C, VP-16 | 88 | 146 | 4.1 | 2.43 | CR | CR, 22 mo+ |
Patient no. . | Sex/age, y . | LVEF, % . | Previous treatment . | Creatinine level, μM . | Na level, mM . | K level, mM . | Ca level, mM . | Status* . | Outcome† . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F/40 | 55 | ATRA, Dauno | 81 | 141 | 3.7 | 2.41 | CR | CR, 22 mo+ |
| 2 | F/49 | 78 | ATRA, Dauno, VP-16, Ara-C, IDA | 85 | 142 | 3.5 | 2.47 | CR | CR, 85 mo+ |
| 3 | F/35 | 75 | ATRA, Dauno, VP-16, IDA, Ara-C | 59 | 139 | 4.2 | 2.39 | CR | CR, 49 mo+ |
| 4 | F/32 | 65 | ATRA, Dauno, VP-16 | 82 | 141 | 3.8 | 2.46 | CR | CR, 26 mo+ |
| 5 | M/41 | 55 | ATRA, Dauno, Ara-C | 89 | 139 | 2.8 | 2.39 | CR | CR, 55 mo+ |
| 6 | M/76 | 50 | ATRA, Dauno | 146 | 135 | 4.1 | 2.48 | Dead | Sepsis, 15 d |
| 7 | M/46 | 65 | Dauno, VP-16 | 87 | 144 | 3.5 | 2.25 | CR | CR, 26 mo+ |
| 8 | F/55 | 50 | IDA | 87 | 143 | 3.4 | 2.43 | CR | CR, 21 mo+ |
| 9 | M/48 | 50 | ATRA, Dauno, Ara-C, VP-16 | 100 | 140 | 3.6 | 2.38 | CR | CR, 40 mo+ |
| 10 | M/64 | 50 | ATRA, Dauno, Ara-C, IDA | 143 | 141 | 4.3 | 2.27 | CR | CR, 49 mo+ |
| 11 | F/50 | 50 | Dauno, Ara-C, VP-16 | 100 | 137 | 3.9 | 2.30 | CR | CR, 65 mo+ |
| 12 | M/37 | 50 | ATRA, Dauno, Ara-C, VP-16 | 78 | 140 | 3.8 | 2.40 | CR | Dead, R3, 16 mo |
| 13 | M/40 | 65 | ATRA, Dauno, VP-16, Ara-C, IDA | 126 | 135 | 3.7 | 2.33 | CR | CR, 15 mo+ |
| 14 | M/44 | 55 | ATRA, Dauno, Ara-C, VP-16 | 73 | 141 | 3.6 | 2.36 | CR | Dead, TB, 12 mo |
| 15 | M/44 | 50 | ATRA, Dauno, VP-16 | 68 | 142 | 3.6 | 2.38 | CR | CR, 31 mo+ |
| 16 | M/28 | 75 | ATRA, Dauno, VP-16 | 73 | 141 | 3.8 | 2.38 | CR | CR, 11 mo+ |
| 17 | M/31 | 65 | ATRA, Dauno, Ara-C, VP-16 | 88 | 146 | 4.1 | 2.43 | CR | CR, 22 mo+ |
LVEF indicates left ventricular ejection fraction; F, female; ATRA, all-trans retinoic acid; Dauno, daunorubicin; CR, complete remission; Ara-C, cytosine arabinoside; VP-16, etoposide; IDA, idarubicin; M, male; R3, third relapse; TB, tuberculosis.
Status after completion of the first course of oral As2O3.
Status at latest follow-up, with maintenance therapy comprising oral As2O3 (10 mg/d) and ATRA (45 mg/m2/d), given for 2 weeks every 2 months for a planned 2 years.